Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Assunto principal
Intervalo de ano de publicação
1.
J Fam Pract ; 71(6): E13-E15, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35994758

RESUMO

YES. Augmentation with second generation antipsychotics, especially aripiprazole and quetiapine, appears to be effective in patients with moderate-to-severe depression who have had a suboptimal response to a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor (strength of recommendation [SOR]: A, based on a systematic review of randomized controlled trials [RCTs] and an individual RCT). Augmenting antidepressant therapy with cariprazine, ziprasidone, or olanzapine also appears to improve depressive symptoms over the short term. All antipsychotics studied carried an increased likelihood of adverse effects that could lead to discontinuation (SOR: A, based on a systematic review of RCTs).


Assuntos
Antipsicóticos , Antipsicóticos/efeitos adversos , Aripiprazol/efeitos adversos , Benzodiazepinas , Depressão/tratamento farmacológico , Humanos , Olanzapina/uso terapêutico , Fumarato de Quetiapina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA